The FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44% for corneal cystine crystal accumulation in patients with cystinosis.
Ocuphire Pharma submits New Drug Application to FDA for Nyxol eye drops for reversal of mydriasis
New potential mechanism for vision loss discovered
Retinal cells may have potential to protect themselves from diabetic retinopathy
